Nielsen BioSciences, a San Diego-based biopharmaceutical company, has announced that its Phase 3 clinical trial of CANDIN® (Purified Candida albicans Antigen) for treating common warts (Verruca vulgaris) has achieved significant results. The trial, which included 325 patients aged 12 and older across the U.S. and Japan, met its primary endpoint of complete resolution of the injected wart without recurrence over a 12-week period. Additionally, key secondary endpoints were also achieved, including the number of injections required for wart clearance and the clearance of all or over 50% of other measured warts, indicating a systemic effect of the treatment. The trial is notable for being the first placebo-controlled, randomized study for this HPV-driven condition. Nielsen BioSciences aims to submit its findings to the U.S. Food and Drug Administration (FDA) for approval in the latter half of 2026. The company is collaborating with Maruho Co. Ltd, a Japanese pharmaceutical firm, for the commercialization of CANDIN in Japan and other Asian markets.